SC Liver and Perspectum develop clinical network for liver drug trials

15th April 2019 (Last Updated April 15th, 2019 13:33)

US-based SC Liver Research Consortium (SC Liver) has partnered with UK-based digital technologies company Perspectum Diagnostics to develop a clinical network for supporting the development of drugs to treat liver disorders.

The network will provide clinical trial services and comprise multiple private and academic centres sites for trials that would require imaging services.

Perspectum Diagnostics is focused on providing technologies to detect, diagnose and treat liver disease in early stages. The company is also working towards better understanding of liver disease.

SC Liver is a group of physicians who specialise in hepatology and gastroenterology clinical research. The Consortium’s network includes more than 85 research sites.

It offers services for study design, site selection, contract and budget negotiations, and management of a clinical trial.

The partners will leverage their respective experiencer in Phase I-III trials. They intend to combine Perspectum’s expertise in NASH, cholestatic liver disease and HCC with SC Liver’s clinical development, patient recruitment and regulatory approval capabilities.

Perspectum Diagnostics US Operations head Cathy O’Hare said: “Our collaboration with SC Liver has produced several high-performing clinical sites with well-trained imaging centres to provide a high level and quality of service for sponsors.

“This project also makes non-invasive liver health assessment available in further-reaching clinical trials, supporting patient recruitment and accelerating drug development.”

SC Liver head Paul Pockros noted: “This partnership has enabled access to important technology for investigators and facilitates the progress of NASH research.”

Till date, multiple institutions have joined the new clinical network, including Cincinnati Clinical Research, Indiana University School of Medicine and Cedars-Sinai Medical Center.